|
Jan 9
|
How Roche aims to change the 'standard of care'
|
|
Jan 9
|
Sarepta (SRPT) Rises on Solid Q4 and 2023 Preliminary Results
|
|
Jan 9
|
Should You Invest in Roche Holding AG (RHHBY)?
|
|
Jan 8
|
3 Great Foreign Companies to Invest in Right Now
|
|
Jan 5
|
Omega (OMGA) Up 95% on Obesity Drug Deal With Novo Nordisk
|
|
Jan 3
|
Remix Therapeutics Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing
|
|
Jan 3
|
Roche joins startup Remix in bet on another way to drug RNA
|
|
Jan 2
|
Roche to buy LumiraDx’s point-of-care technology for $295M
|
|
Jan 2
|
Roche (RHHBY) to Acquire LumiraDx's Point of Care Technology
|
|
Dec 29
|
Roche to buy part of LumiraDx diagnostics platform for $295 million
|
|
Dec 29
|
Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform
|
|
Dec 26
|
Sarepta (SRPT) Seeks Label Expansion for DMD Gene Therapy
|
|
Dec 21
|
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
|
|
Dec 20
|
Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag
|
|
Dec 20
|
This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to Know
|
|
Dec 19
|
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
|
|
Dec 19
|
Roche navify digital solutions get excellent ratings from healthcare professionals in KLAS Research reports
|
|
Dec 9
|
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A
|
|
Dec 9
|
New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A
|
|
Dec 8
|
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
|